Novartis Pharma B.V.
Location
Noord-Holland
Founded
1948-02-10
Website
Risk Signals
21161 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Drugs, Drug Proprietaries, and Druggists' Sundries), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Novartis Pharma B.V.
Live alerts from global media, monitored by Business Radar
2025-07-10 (investors.com)
Stocks Generating Improved Relative Strength: Novartis ADR | Investor's Business Daily
A Relative Strength Rating upgrade for Novartis ADR shows improving technical performance. Will it continue?
Read more
2025-07-10 (biospectator.com)
Novartis , Shiro Nax and ' BBB Platform ' 1.75 billion 弗 Optional Deal -
Novartis bought an option for $ 175 million for the option to acquire the BBB transmission platform from China -based Global Biotech Shironax.
Read more
2025-07-10 (biopharmadive.com)
Renasant Bio, chasing drugs for ADPKD, raises $55M in seed funding |
The biotech is taking inspiration from cystic fibrosis treatment and applying a similar approach to developing "corrector" and "potentiator" medicines for the kidney disease.
Read more
2025-07-09 (aijourn.com)
$14 Billion Cell and Gene Therapy Market to Double by 2030, Driven by Oncology and RNA Breakthroughs, reports Kalorama Information |
ARLINGTON, Va., July 9, 2025 /PRNewswire/ -- Kalorama Information, a leading authority in healthcare market research, announces the release of its new report,
Read more
2025-07-09 (razon.com.mx)
Inflation slows down after rebound; Low to 4.32% in June -
After four months, the National Consumer Price Index (INPC) decelerated until positioning in 4.32 percent per year during June. According to the National Institute of Statistics and Geography (INEGI), the INPC level was 140,405, which represented an increased of 0.28 percent compared to the previous month. "In the same month of 2024, monthly inflation was 0.38 percent; the annual, 4.98 percent," he said.
Read more
2025-07-09 (medinside.ch)
Swissmedic allows new malaria for babies
The Novartis drug Riamet Baby is newly approved in Switzerland. It should work against malaria in small children.
Read more
2025-07-09 (cash.ch)
Novartis works with Sironax to overcome the blood-brain barrier | cash
Novartis enters an agreement with the Chinese biotech company Sironax a strategic agreement.
Read more
2025-07-09 (apotheke-adhoc.de)
Nulletax: "Doctor number wrong, 2300 euros away" |
Because a doctor had given a recipe with a pseudo doctor number, the rose pharmacy in Hainichen received retaxation in the four-digit range. "The pharmacies are not at all in the obligation to check," said pharmacist Karl-Peter Jahn, who has already contradicted the cut.
Read more
2025-07-09 (endpoints.news)
Novartis' brain delivery platform option deal worth up to $175M; Neumora's next steps
Plus, news about Vie Ventures, Jasper Therapeutics, Jim Wilson's GEMMABio Therapeutics, Gilead's lenacapavir, Atsena Therapeutics, Leo Pharma and Cogent Biosciences.
Read more
2025-07-09 (prnewswire.com)
Sironax Grants Novartis Exclusive Option to Acquire its Brain Delivery Platform While Retaining Rights to Advance Selected Therapeutic Assets APAC - English APAC - Traditional Chinese USA - English USA - English
/PRNewswire/ -- Sironax, a clinical-stage biotech company dedicated to the discovery and development of transformational therapies for age-related diseases,...
Read more
2025-07-09 (lesechos.fr)
Donald Trump releases the sulfater on pharmaceutical products, threatened by 200% customs duties |
The President threatens XXL customs duties laboratories on pharmaceutical products imported into the United States. Its signature recipe for forcing industrialists to move their factories on American soil. The Sanofi action is at the bottom of the CAC 40 ranking this Wednesday, but the market wonders about the reality of the threat.
Read more
2025-07-09 (koreabiomed.com)
Pluvicto enters clinical use in Korea amid growing interest in radioligand therapy for prostate cancer < Pharma < Article -
Novartis' Pluvicto, a next-generation radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC), has begun clinical use in Korea following regulatory approval, offering new hope to patients with limited treatment options.Although not yet reimbursed under the national health ins
Read more